[Management of side effects of targeted therapies in renal cancer: nephrological side effects].

Author: IzzedineHassan, NeuzilletYann, NégrierSylvie, ZiniLaurent

Paper Details 
Original Abstract of the Article :
Several types of nephrological side-effects can occur during treatment with targeted therapy: high blood pressure, proteinuria, thrombotic microangiopathy, kidney failure, etc. Screening and treatment for high blood pressure, proteinuria and kidney failure are recommended during treatment with molec...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1684/bdc.2011.1449

データ提供:米国国立医学図書館(NLM)

Management of Side Effects of Targeted Therapies in Renal Cancer

This research focuses on the nephrological side effects of targeted therapies used in the treatment of renal cancer. The study provides a comprehensive overview of the potential complications that may arise during targeted therapy, emphasizing the importance of careful monitoring and management to ensure patient safety and optimize treatment outcomes.

Navigating the Desert of Renal Cancer Treatment

This research highlights the importance of careful monitoring and management of nephrological side effects during targeted therapy for renal cancer. The study provides valuable guidance for clinicians, emphasizing the need for regular blood pressure monitoring, proteinuria screening, and close attention to potential complications like thrombotic microangiopathy.

Renal Cancer Treatment: A Balancing Act

Treating renal cancer is like navigating a complex desert landscape, balancing the benefits of targeted therapies with the potential risks of side effects. This research provides a valuable roadmap for clinicians, helping them to manage these complexities and ensure the optimal care of their patients.

Dr. Camel's Conclusion

This research emphasizes the need for a careful and vigilant approach to managing the side effects of targeted therapies in renal cancer. It's like navigating a challenging desert, where constant monitoring and adjustments are crucial for ensuring patient safety and well-being.
Date :
  1. Date Completed 2015-03-31
  2. Date Revised 2015-03-30
Further Info :

Pubmed ID

25819129

DOI: Digital Object Identifier

10.1684/bdc.2011.1449

Related Literature

SNS
PICO Info
in preparation
Languages

French

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.